All Clinical Trials

A listing of 23128 clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Trials

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Type 2 Diabetes Clinical Trial

Recruiting

Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.

Conditions:

Type 2 Diabetes

Diabetes Mellitus Type 2 in Obese

Diabetes Type Two

Type 2 Diabetes Mellitus

Diabete Type 2

Learn More

Featured Offer

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

Studies of Blood Flow to the Brain During Thought

NCT00001360

Recruiting

The purpose of this study is to use brain imaging technology to measure changes in blood flow to areas in the brain as individuals perform intellectual tasks. This study will use functional magnetic resonance imaging (fMRI) to examine blood flow to areas of the brain as participants engage in tasks associated with visual perception, visual recognition, and memory....

Gender:

ALL

Ages:

Between 18 years and 65 years

Trial Updated:

05/09/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Healthy Volunteer

Learn More ›

Natural History of Glycosphingolipid Storage Disorders and Glycoprotein Disorders

NCT00029965

Recruiting

Study description: This is a natural history study that will evaluate any patient with enzyme or DNA confirmed GM1 or GM2 gangliosidosis, sialidosis or galactosialidosis. Patients may be evaluated every 6 months for infantile onset disease, yearly for juvenile onset and approximately every two years for adult-onset disease as long as they are clinically stable to travel. Data will be evaluated serially for each patient, and cross-sectionally for patients of similar ages and genotypes. Genotype-phenotype correlations will be made where possible although these are rare disorders and the majority of the patients are compound heterozygotes. Objectives: To study the natural history and progression of neurodegeneration in individuals with glycosphingolipid storage disorders (GSL), GM1 and GM2 gangliosidosis, and glycoprotein (GP) disorders including sialidosis and galactosialidosis using clinical evaluation of patients and patient/parent surveys. To develop sensitive tools for monitoring disease progression. To identify biological markers in blood, cerebrospinal fluid, and urine that correlate with disease severity and progression and can be used as outcome measures for future clinical trials. To further understand and characterize the mechanisms of neurodegeneration in GSL and GP storage disorders across the spectrum of disease beginning with ganglioside storage in fetal life. Endpoints: Exploring the natural history of Lysosomal Storage Diseases and Glycoprotein Disorders Study Population: Patients with enzyme or DNA confirmed GM1 or GM2 gangliosidosis, sialidosis or galactosialidosis. Accrual ceiling is 200 participants. No exclusions based on age, gender, demographic group, or demographic location. Patients included in our study are those that are seen at the NIH Clinical Center, subjects that have only sent in blood samples, as well as those who complete the questionnaire or provided head circumference measures. Read Less

Gender:

ALL

Ages:

Between 1 day and 100 years

Trial Updated:

05/09/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Neurological Regression, Myoclonus, Cherry Red Spot, Brain Atrophy

Learn More ›

Causes and Natural History of Dyslipidemias

NCT00353782

Recruiting

This study will evaluate people with dyslipidemias - disorders that affect the fat content in the blood. Fats, or lipids, such as cholesterol and triglycerides, are carried in the blood in particles called lipoproteins. These particles are involved in causing blood vessel diseases that can lead to conditions like atherosclerosis (hardening of the arteries) or heart attack. Participants will undergo accepted medical tests and procedures to evaluate their condition. Most of the test results are helpful in making a diagnosis and in guiding treatment. People with lipid disorders are eligible for this study. Representative types of patients include those with: * Plasma cholesterol levels greater than 200 mg/dl or less than 120 mg/dl * Plasma LDL-C levels greater than 130 mg/dl or less than 70 mg/dl * Plasma HDL-C levels greater than 70 mg/dl or less than 25 mg/dl * Unusual cholesterol deposits or xanthomas (nodules of lipid deposits on the skin) Children under 2 years of age are excluded from the study. Participants will undergo some or all of the following procedures: * Plasma evaluation. Apolipoproteins (plasma proteins involved in metabolism of cholesterol, triglycerides, phospholipids, and proteins in the blood) and enzymes involved in lipid metabolism are measured. * Fat biopsy. A small sample of fat tissue is collected for examination. For this test, an area on the buttock or abdominal wall is numbed. A needle is inserted into the fat, and a small amount of tissue is sucked out by a syringe. * Leukapheresis. White blood cells are collected to help diagnose the lipid disorder. For this test, blood is collected through a needle in an arm vein, similar to donating blood. The blood circulates through a machine that separates it into its components, and the white cells are removed. The rest of the blood is returned to the body, either through the same needle or through another needle in the other arm. * Skin biopsy. Skin cells are collected for study. The cells are grown in the laboratory and the amount of cholesterol that enters or leaves the cells is measured, providing information on abnormalities in cholesterol transport. For this test, an area of skin is numbed with an anesthetic and a small circular area is removed, using a skin punch instrument similar to a sharp cookie cutter. * Heparin infusion study. Heparin, a blood thinner, releases enzymes that break down fat in the blood. Lipase activity (breakdown of fats) in the blood is measured following the injection of heparin into a vein. Read Less

Gender:

ALL

Ages:

Between 2 years and 100 years

Trial Updated:

05/09/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Hypercholesterolemia, Atherosclerosis

Learn More ›

Genotype-Phenotype Study of Patients With Plaquenil -Induced Retinal Toxicity, With Evaluation of the ABCA4 Gene

NCT01145196

Recruiting

Background: - Plaquenil (hydroxychloroquine) is an anti-inflammatory drug that is used to treat some autoimmune diseases such as lupus and rheumatoid arthritis. This drug can damage the retina by causing a condition called plaquenil-induced retinal toxicity, which may lead to vision loss. However, most people taking plaquenil do not develop this problem. Researchers are interested in studying whether differences in a person s genes explain why some people develop plaquenil-induced retinal toxic... Read More

Gender:

ALL

Ages:

Between 18 years and 120 years

Trial Updated:

05/09/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Genotype, Retinal Disease

Learn More ›

Deep Brain Stimulation Surgery for Movement Disorders

NCT01581580

Recruiting

Background: - Deep brain stimulation (DBS) is an approved surgery for certain movement disorders, like Parkinson's disease, that do not respond well to other treatments. DBS uses a battery-powered device called a neurostimulator (like a pacemaker) that is placed under the skin in the chest. It is used to stimulate the areas of the brain that affect movement. Stimulating these areas helps to block the nerve signals that cause abnormal movements. Researchers also want to record the brain function... Read More

Gender:

ALL

Ages:

Between 18 years and 99 years

Trial Updated:

05/09/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Parkinson's Disease, Essential Tremor, Dystonia

Learn More ›

Deep Brain Stimulation Therapy in Movement Disorders

NCT02119611

Recruiting

Background: - In deep brain stimulation (DBS), a device called a neurostimulator is placed in the chest. It is attached to wires in parts of the brain that affect movement. DBS might help people with movement disorders like Parkinson s disease (PD), dystonia, and essential tremor (ET). Objective: - To provide DBS treatment to people with some movement disorders. Eligibility: - Adults 18 years and older with PD, ET, or certain forms of dystonia. Design: * Participants will be screened with... Read More

Gender:

ALL

Ages:

Between 18 years and 100 years

Trial Updated:

05/09/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Parkinson's Disease

Learn More ›

Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers

NCT02830724

Recruiting

Background: In a new cancer therapy, researchers take a person s blood, select a certain white blood cell to grow in the lab, and then change the genes of these cells using a virus. The cells are then given back to the person. This is called gene transfer. For this study, researchers will modify the person s white blood cells with anti-CD70. Objectives: To see if a gene transfer with anti-CD70 cells can safely shrink tumors and to be certain the treatment is safe. Eligibility: Adults age 18... Read More

Gender:

ALL

Ages:

Between 18 years and 72 years

Trial Updated:

05/09/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Pancreatic Cancer, Renal Cell Cancer, Breast Cancer, Melanoma, Ovarian Cancer

Learn More ›

Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies

NCT04235777

Recruiting

Background: Genitourinary cancers are some of the most common types of cancer. They are lethal when they spread. The drug M7824 blocks the paths that cancer cells use to stop the immune system from fighting cancer. The drug PDS01ADC triggers the immune system to fight cancer. Researchers want to learn if these drugs can help fight these cancers when given with and without Stereotactic Body Radiation Therapy (SBRT) radiation. Objective: To learn if M7824 and PDS01ADC, with or without SBRT, can... Read More

Gender:

ALL

Ages:

Between 18 years and 120 years

Trial Updated:

05/09/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Urothelial Cancer, Bladder Cancer, Genitourinary Cancer, Urogenital Neoplasms, Urogenital Cancer

Learn More ›

A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

NCT05221840

Recruiting

This is a Phase III, randomised, double-blind, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) in combination with oleclumab (MEDI9447) or durvalumab (MEDI4736) with monalizumab (IPH2201) in adults with locally advanced (Stage III), unresectable NSCLC, who have not progressed following platinum-based cCRT.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/09/2025

Locations: Research Site, San Diego, California +240 locations

Research Site, San Diego, California

Research Site, New Haven, Connecticut

Research Site, Stuart, Florida

Research Site, Urbana, Illinois

Research Site, New Albany, Indiana

Research Site, Waterloo, Iowa

Research Site, Lexington, Kentucky

Research Site, Louisville, Kentucky

Research Site, Scarborough, Maine

Research Site, Annapolis, Maryland

Research Site, Baltimore, Maryland

Research Site, Bethesda, Maryland

Research Site, Grand Rapids, Michigan

Research Site, Duluth, Minnesota

Research Site, Southaven, Mississippi

Research Site, Billings, Montana

Research Site, Ridgewood, New Jersey

Research Site, Ithaca, New York

Research Site, Middletown, New York

Research Site, Greensboro, North Carolina

Research Site, Cleveland, Ohio

Research Site, Independence, Ohio

Research Site, Maumee, Ohio

Research Site, Portland, Oregon

Research Site, Philadelphia, Pennsylvania

Research Site, York, Pennsylvania

Research Site, Sioux Falls, South Dakota

Research Site, Houston, Texas

Research Site, Charlottesville, Virginia

Research Site, Fairfax, Virginia

Research Site, Fredericksburg, Virginia

Research Site, Richmond, Virginia

Research Site, Richland, Washington

Research Site, Spokane, Washington

Research Site, Tacoma, Washington

Research Site, Milwaukee, Wisconsin

Research Site, Box Hill, Not set

Research Site, East Melbourne, Not set

Research Site, Elizabeth Vale, Not set

Research Site, Gosford, Not set

Research Site, Heidelberg, Not set

Research Site, Kogarah, Not set

Research Site, South Brisbane, Not set

Research Site, St Albans, Not set

Research Site, St. Leonards, Not set

Research Site, Westmead, Not set

Research Site, Barretos, Not set

Research Site, Belo Horizonte, Not set

Research Site, Florianópolis, Not set

Research Site, Fortaleza, Not set

Research Site, Jaú, Not set

Research Site, Natal, Not set

Research Site, Porto Alegre, Not set

Research Site, Recife, Not set

Research Site, Sao Paulo, Not set

Research Site, Uberlândia, Not set

Research Site, Vitoria, Not set

Research Site, Edmonton, Alberta

Research Site, Barrie, Ontario

Research Site, Hamilton, Ontario

Research Site, Kingston, Ontario

Research Site, London, Ontario

Research Site, Mississauga, Ontario

Research Site, Toronto, Ontario

Research Site, Rimouski, Quebec

Research Site, Anyang, Not set

Research Site, Beijing, Not set

Research Site, Changchun, Not set

Research Site, Changsha, Not set

Research Site, Chongqing, Not set

Research Site, Guangzhou, Not set

Research Site, Hangzhou, Not set

Research Site, Hefei, Not set

Research Site, Jieyang, Not set

Research Site, Kunming, Not set

Research Site, Linhai, Not set

Research Site, Nanchang, Not set

Research Site, Nanning, Not set

Research Site, Nantong, Not set

Research Site, Neijiang, Not set

Research Site, Ningbo, Not set

Research Site, Shanghai, Not set

Research Site, Shaoguan, Not set

Research Site, Shenyang, Not set

Research Site, Tianjin, Not set

Research Site, Wuhan, Not set

Research Site, Zhanjiang, Not set

Research Site, Zhengzhou City, Not set

Research Site, Zhengzhou, Not set

Research Site, Zhongshan, Not set

Research Site, Zhuhai, Not set

Research Site, Barranquilla, Not set

Research Site, Bogota D.C., Not set

Research Site, Bogotá, Not set

Research Site, Medellin, Not set

Research Site, Valledupar, Not set

Research Site, Avignon Cedex 9, Not set

Research Site, Besançon Cedex, Not set

Research Site, Bordeaux, Not set

Research Site, Clermont-Ferrand, Not set

Research Site, Creteil Cedex, Not set

Research Site, Lorient cedex, Not set

Research Site, Marseille Cedex 20, Not set

Research Site, Montpellier, Not set

Research Site, Paris Cedex 5, Not set

Research Site, Rennes, Not set

Research Site, Rouen, Not set

Research Site, Toulouse CEDEX 09, Not set

Research Site, Villejuif Cedex, Not set

Research Site, Erfurt, Not set

Research Site, Erlangen, Not set

Research Site, Essen, Not set

Research Site, Esslingen, Not set

Research Site, Georgsmarienhuette, Not set

Research Site, Guetersloh, Not set

Research Site, Hannover, Not set

Research Site, Oldenburg, Not set

Research Site, Würzburg, Not set

Research Site, Brescia, Not set

Research Site, Firenze, Not set

Research Site, Lucca, Not set

Research Site, Meldola, Not set

Research Site, Orbassano, Not set

Research Site, Parma, Not set

Research Site, Pavia, Not set

Research Site, Roma, Not set

Research Site, Himeji-shi, Not set

Research Site, Hiroshima-shi, Not set

Research Site, Kashiwa, Not set

Research Site, Kurume-shi, Not set

Research Site, Natori-shi, Not set

Research Site, Niigata-shi, Not set

Research Site, Osaka-shi, Not set

Research Site, Sendai-shi, Not set

Research Site, Tokushima-shi, Not set

Research Site, Toon-shi, Not set

Research Site, Wakayama-shi, Not set

Research Site, Changwon-si, Not set

Research Site, Cheongju-si, Not set

Research Site, Seongnam-si, Not set

Research Site, Seoul, Not set

Research Site, Suwon-si, Not set

Research Site, Suwon, Not set

Research Site, Arequipa, Not set

Research Site, Concepción, Not set

Research Site, Lima, Not set

Research Site, Trujillo, Not set

Research Site, Brzozów, Not set

Research Site, Bydgoszcz, Not set

Research Site, Gdańsk, Not set

Research Site, Koszalin, Not set

Research Site, Poznań, Not set

Research Site, Siedlce, Not set

Research Site, Tomaszów Mazowiecki, Not set

Research Site, Warszawa, Not set

Research Site, Alcabideche, Not set

Research Site, Coimbra, Not set

Research Site, Lisboa, Not set

Research Site, Loures, Not set

Research Site, Porto, Not set

Research Site, Novosibirsk, Not set

Research Site, Yekaterinburg, Not set

Research Site, Barcelona, Not set

Research Site, Granada, Not set

Research Site, Madrid, Not set

Research Site, Santiago de Compostela, Not set

Research Site, Valencia, Not set

Research Site, Hsinchu, Not set

Research Site, Taichung, Not set

Research Site, Taipei 112, Not set

Research Site, Taipei, Not set

Research Site, Taoyuan City, Not set

Research Site, Bangkok, Not set

Research Site, Hat Yai, Not set

Research Site, Khon Kaen, Not set

Research Site, Lampang, Not set

Research Site, Muang, Not set

Research Site, Mueang, Not set

Research Site, Naimuang, Not set

Research Site, Ankara, Not set

Research Site, Diyarbakir, Not set

Research Site, Goztepe Istanbul, Not set

Research Site, Karsiyaka, Not set

Research Site, Chernihiv, Not set

Research Site, Kharkiv Region, Not set

Research Site, Kropyvnytskyi, Not set

Research Site, Kyiv, Not set

Research Site, Uzhgorod, Not set

Research Site, Zaporizhzhia, Not set

Research Site, Belfast, Not set

Research Site, Bristol, Not set

Research Site, Dundee, Not set

Research Site, Edinburgh, Not set

Research Site, Hampshire, Not set

Research Site, London, Not set

Research Site, Middlesborough, Not set

Research Site, Poole, Not set

Research Site, Rhyl, Not set

Research Site, Torquay, Not set

Research Site, Truro, Not set

Research Site, Wolverhampton, Not set

Research Site, Hai Phong, Not set

Research Site, Hanoi, Not set

Research Site, Ho Chi Minh city, Not set

Research Site, Ho Chi Minh, Not set

Conditions: Non-Small Cell Lung Cancer

Learn More ›

Blinded Efficacy and Safety Study of CAL02 IV Plus SOC in Subjects With Severe Community-Acquired Bacterial Pneumonia

NCT05776004

Recruiting

This is a placebo-controlled study to evaluate the addition of CAL02 to standard of care in treating hospitalized subjects diagnosed with severe community acquired bacterial pneumonia (SCABP) requiring critical care measures

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/09/2025

Locations: UCSF Hospital, Fresno, California +95 locations

UCSF Hospital, Fresno, California

UF Health Shands Hospital, Gainesville, Florida

Northwestern Memorial Hospital, Chicago, Illinois

University of Nebraska Medical Center, Omaha, Nebraska

Wake Forest Baptist Health Hospital, Winston-Salem, North Carolina

Cleveland Clinic Fairview Hospital, Cleveland, Ohio

University of Texas Medical Branch, Galveston, Texas

Hospital Interzonal General de Agudo Dr Jose Pena, Bahía Blanca, Buenos Aires

Hospital de Alta Complejidad Cuenca Alta SAMIC, Cañuelas, Buenos Aires

Hospital Italiano de Buenos Aires, Ciudad Autonoma de Buenos Aires, Buenos Aires

Hospital Misericordia Nuevo Siglo, Córdoba, Not set

Hospital Central, Mendoza, Not set

Hospital Zonal General de Agudos, Moreno, Not set

Clinique Universitaire Saint Luc, Bruxelles, Not set

Clinique Saint Pierre, Ottignies, Not set

Chu-Ucl-Namur, Yvoir, Not set

Santa Casa de Curitiba, Curitiba, Parana

Hospital Mae de Deus, Porto Alegre, Rio Grande Do Sul

Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto, São José Do Rio Preto, Sao Paulo

Unidade de Pesquisa Clinica da Faculdade de Medicina de Botucatu, Botucatu, Not set

Hospital do Servidor Publico Estadual, São Paulo, Not set

Foothills Hospital Medical Centre, Calgary, Alberta

Peter Lougheed Centre, Calgary, Alberta

Rockyview General Hospital, Calgary, Alberta

South Health Campus Hospital, Calgary, Alberta

Saint Paul's Hospital, Vancouver, Not set

Pontificia Universidad Catolica de Chile, Santiago, Not set

Centro de Investigacion Clinica de la Costa SAS, Barranquilla, Not set

Fundacion Cardioinfantil - Instituto de Cardiologia, Bogotá, Not set

Fundacion Cardiovascular de Colombia, Piedecuesta, Not set

Všeobecná fakultní nemocnice - Klinika anesteziologie, resuscitace a intenzivní medicíny (KARIM), Praha, Not set

Krajska Zdravotni, a.s., Teplice, Not set

Oblastní nemocnice Kolín, a.s., nemocnice Středočeského kraje, Zizkova, Not set

Krajska Zdravotni, a.s., Ústí Nad Labem, Not set

CHD Vendee, La Roche-sur-Yon, Vendee

CHU Angers, Angers, Not set

Centre Hospitalier Victor Dupouy, Argenteuil, Not set

Hopital Nord Franche Comte, Belfort, Not set

Hospital Fleyriat, Bourg-en-Bresse, Not set

Centre Hospitalier de Dieppe, Dieppe, Not set

Plateforme de Biologie Hospitalo-Universitaire, Dijon, Not set

Hopital Raymond Poincare, Garches, Not set

Pole Urgences Medecine Aigue CHU de Grenoble-Alpes, Grenoble, Not set

Hospital Dupuytren, Limoges, Not set

Centre Hospitalier de Melun-Senart, Melun, Not set

CHU de Nantes, Nantes, Not set

Hopitaux Universitaires de Strasbourg - Nouvel Hopital Civil, Strasbourg, Not set

Centre Hospitalier Bretagne Atlantique, Vannes, Not set

LTD Batumi Medical Center, Batumi, Not set

JSC Rustavi Central Hospital, Rust'avi, Not set

LLC Aleksandre Aladashvili Clinic, Tbilisi, Not set

LTD Tbilisi Central Hospital, Tbilisi, Not set

LTD Simon Khechinashvili University Hospital, Tbilisi, Not set

The First Medical Center LTD, Tbilisi, Not set

LTD N5 Clinical Hospital, Tbilisi, Not set

Thoracic General Hospital, Athens, Not set

University General Hospital Attikon, Athens, Not set

University General Hospital, Heraklion, Not set

Bekes Varmegyei Kozponti K6rhaz, Gyula, Not set

Szaboles-Szatmar-Bereg Varmegyei Oktatokorhaz, Nyiregyhaza, Not set

Borsod-Abauj-Zemplen Varmegyei Kozponti Korhaz es Egyetemi Oktatov, Szentpeteri Kapu, Not set

Zala Varmegyei Szent Rafael Korbaz, Zalaegerszeg, Not set

Liepajas Regional Hospital, Liepāja, Not set

Pauls Stradins Clinical University Hospital, Riga, Not set

Vidzemes Hospital, Valmiera, Not set

Hospital Nacional III, Arequipa, Not set

Clinica Ricardo Palma, Lima, Not set

Clinica San Pablo-Sede Surco, Lima, Not set

Hospital Nacional Edgardo Rebagliati, Lima, Not set

Hospital de la Amistad, Piura, Not set

Pius Brinzeu County Emergency Clinical Hospital, Timişoara, Judet Timis

Elias University Emergency Hospital, Bucharest, Not set

Fundeni Clinical Institute, Bucharest, Not set

Cluj County Emergency Clinical Hospital, Cluj-Napoca, Not set

Bihor County Emergency Clinical Hospital, Oradea, Not set

University Clinical Centre of Serbia, Belgrad, Not set

University Clinical Centre, Kragujevac, Not set

University Clinical Centre, Niš, Not set

Institute for Pulmonary Diseases, Sremska Kamenica, Not set

Univerzitna nemocnica, Martin, Not set

Helen Joseph Academic Hospital, Johannesburg, Gauteng

FCRN Clinical Trial Centre, Vereeniging, Gauteng

Tygerberg Hospital, Cape Town, Not set

TASK Eden, George, Not set

Ryexo Clinical Research, Pretoria, Not set

Dr JM Engelbrecht Trial Site, Somerset West, Not set

Hospital Universitari Vall d'Hebron, Barcelona, Not set

Parc Tauli Hospital Universitari, Barcelona, Not set

Hospital Clinico San Carlos, Madrid, Not set

Hospital Universitario Infanta Leonor, Madrid, Not set

C.H.U de Santiago de Compostela, Santiago De Compostela, Not set

Hospital Universitario de Tarragona Joan XXIII, Tarragona, Not set

Hospital Universitari Mutua Terrassa, Terrassa, Not set

Hospital Universitario de Toledo, Toledo, Not set

Hospital Universitario Dr Peset, Valencia, Not set

Hospital Clínico Universitario de Valladolid, Valladolid, Not set

Conditions: Pneumonia, Bacterial

Learn More ›

A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

NCT06215716

Recruiting

This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with non-cirrhotic NASH/MASH and fibrosis stage 2 or 3 (F2 or F3). The study will enroll subjects in two cohorts for a total samples size of 1650 subjects.

Gender:

ALL

Ages:

Between 18 years and 80 years

Trial Updated:

05/09/2025

Locations: Akero Clinical Study Site, Birmingham, Alabama +309 locations

Akero Clinical Study Site, Birmingham, Alabama

Akero Clinical Study Site, Dothan, Alabama

Akero Clinical Study Site, Chandler, Arizona

Akero Clinical Study Site, Flagstaff, Arizona

Akero Clinical Study Site, Mesa, Arizona

Akero Clinical Study Site, Peoria, Arizona

Akero Clinical Study Site, Tucson, Arizona

Akero Clinical Study Site, Conway, Arkansas

Akero Clinical Study Site, Jonesboro, Arkansas

Akero Clinical Study Site, Little Rock, Arkansas

Akero Clinical Study Site, North Little Rock, Arkansas

Akero Clinical Study Site, Chula Vista, California

Akero Clinical Study Site, Coronado, California

Akero Clinical Study Site, Folsom, California

Akero Clinical Study Site, Inglewood, California

Akero Clinical Study Site, La Mesa, California

Akero Clinical Study Site, Lancaster, California

Akero Clinical Study Site, Long Beach, California

Akero Clinical Study Site, Los Angeles, California

Akero Clinical Study Site, Newport Beach, California

Akero Clinical Study Site, Orange, California

Akero Clinical Study Site, Palm Springs, California

Akero Clinical Study Site, Pasadena, California

Akero Clinical Study Site, Redwood City, California

Akero Clinical Study Site, San Diego, California

Akero Clinical Study Site, San Francisco, California

Akero Clinical Study Site, Santa Maria, California

Akero Clinical Study Site, Aurora, Colorado

Akero Clinical Study Site, Colorado Springs, Colorado

Akero Clinical Study Site, Englewood, Colorado

Akero Clinical Study Site, New Haven, Connecticut

Akero Clinical Study Site, Bradenton, Florida

Akero Clinical Study Site, Brandon, Florida

Akero Clinical Study Site, Doral, Florida

Akero Clinical Study Site, Fort Myers, Florida

Akero Clinical Study Site, Gainesville, Florida

Akero Clinical Study Site, Hialeah Gardens, Florida

Akero Clinical Study Site, Inverness, Florida

Akero Clinical Study Site, Jacksonville, Florida

Akero Clinical Study Site, Lady Lake, Florida

Akero Clinical Study Site, Lakewood Ranch, Florida

Akero Clinical Study Site, Largo, Florida

Akero Clinical Study Site, Maitland, Florida

Akero Clinical Study Site, Margate, Florida

Akero Clinical Study Site, Miami Gardens, Florida

Akero Clinical Study Site, Miami Lakes, Florida

Akero Clinical Study Site, Miami, Florida

Akero Clinical Study Site, Naples, Florida

Akero Clinical Study Site, New Port Richey, Florida

Akero Clinical Study Site, Ocala, Florida

Akero Clinical Study Site, Orlando, Florida

Akero Clinical Study Site, Pembroke Pines, Florida

Akero Clinical Study Site, Port Orange, Florida

Akero Clinical Study Site, Sarasota, Florida

Akero Clinical Study Site, Temple Terrace, Florida

Akero Clinical Study Site, Venice, Florida

Akero Clinical Study Site, Viera, Florida

Akero Clinical Study Site, West Palm Beach, Florida

Akero Clinical Study Site, Winter Park, Florida

Akero Clinical Study Site, Columbus, Georgia

Akero Clinical Study Site, Gainesville, Georgia

Akero Clinical Study Site, Marietta, Georgia

Akero Clinical Study Site, Chicago, Illinois

Akero Clinical Study Site, Hammond, Indiana

Akero Clinical Study Site, South Bend, Indiana

Akero Clinical Study Site, West Des Moines, Iowa

Akero Clinical Study Site, Topeka, Kansas

Akero Clinical Study Site, Wichita, Kansas

Akero Clinical Study Site, Louisville, Kentucky

Akero Clinical Study Site, Bastrop, Louisiana

Akero Clinical Study Site, Covington, Louisiana

Akero Clinical Study Site, Houma, Louisiana

Akero Clinical Study Site, Marrero, Louisiana

Akero Clinical Study Site, Metairie, Louisiana

Akero Clinical Study Site, New Orleans, Louisiana

Akero Clinical Study Site, Shreveport, Louisiana

Akero Clinical Study Site, Baltimore, Maryland

Akero Clinical Study Site, Glen Burnie, Maryland

Akero Clinical Study Site, Greenbelt, Maryland

Akero Clinical Study Site, South Dartmouth, Massachusetts

Akero Clinical Study Site, Southfield, Michigan

Akero Clinical Study Site, Wyoming, Michigan

Akero Clinical Study Site, Ypsilanti, Michigan

Akero Clinical Study Site, Columbia, Missouri

Akero Clinical Study Site, Kansas City, Missouri

Akero Clinical Study Site, Las Vegas, Nevada

Akero Clinical Study Site, Reno, Nevada

Akero Clinical Study Site, Florham Park, New Jersey

Akero Clinical Study Site, Somers Point, New Jersey

Akero Clinical Study Site, Sparta, New Jersey

Akero Clinical Study Site, Santa Fe, New Mexico

Akero Clinical Study Site, New York, New York

Akero Clinical Study Site, Chapel Hill, North Carolina

Akero Clinical Study Site, Charlotte, North Carolina

Akero Clinical Study Site, Durham, North Carolina

Akero Clinical Study Site, Fayetteville, North Carolina

Akero Clinical Study Site, Morehead City, North Carolina

Akero Clinical Study Site, New Bern, North Carolina

Akero Clinical Study Site, Raleigh, North Carolina

Akero Clinical Study Site, Statesville, North Carolina

Akero Clinical Study Site, Columbus, Ohio

Akero Clinical Study Site, Dayton, Ohio

Akero Clinical Study Site, Springboro, Ohio

Akero Clinical Study Site, Westlake, Ohio

Akero Clinical Study Site, Medford, Oregon

Akero Clinical Study Site, Philadelphia, Pennsylvania

Akero Clinical Study Site, Pittsburgh, Pennsylvania

Akero Clinical Study Site, Columbia, South Carolina

Akero Clinical Study Site, Summerville, South Carolina

Akero Clinical Study Site, Chattanooga, Tennessee

Akero Clinical Study Site, Clarksville, Tennessee

Akero Clinical Study Site, Hermitage, Tennessee

Akero Clinical Study Site, Nashville, Tennessee

Akero Clinical Study Site, Amarillo, Texas

Akero Clinical Study Site, Austin, Texas

Akero Clinical Study Site, Bellaire, Texas

Akero Clinical Study Site, Brownsville, Texas

Akero Clinical Study Site, Corpus Christi, Texas

Akero Clinical Study Site, Dallas, Texas

Akero Clinical Study Site, Denison, Texas

Akero Clinical Study Site, Edinburg, Texas

Akero Clinical Study Site, Fort Worth, Texas

Akero Clinical Study Site, Houston, Texas

Akero Clinical Study Site, Lewisville, Texas

Akero Clinical Study Site, McAllen, Texas

Akero Clinical Study Site, San Antonio, Texas

Akero Clinical Study Site, San Marcos, Texas

Akero Clinical Study Site, Waco, Texas

Akero Clinical Study Site, Webster, Texas

Akero Clinical Study Site, Wichita Falls, Texas

Akero Clinical Study Site, Ogden, Utah

Akero Clinical Study Site, Salt Lake City, Utah

Akero Clinical Study Site, Sandy, Utah

Akero Clinical Study Site, South Ogden, Utah

Akero Clinical Study Site, Falls Church, Virginia

Akero Clinical Study Site, Newport News, Virginia

Akero Clinical Study Site, Norfolk, Virginia

Akero Clinical Study Site, Richmond, Virginia

Akero Clinical Study Site, Roanoke, Virginia

Akero Clinical Study Site, Suffolk, Virginia

Akero Clinical Study Site, Seattle, Washington

Akero Clinical Study Site, Spokane, Washington

Akero Clinical Study Site, La Plata, Buenos Aires

Akero Clinical Study Site, Ramos Mejia, Buenos Aires

Akero Clinical Study Site, Buenos Aires, Distrito Federal

Akero Clinical Study Site, Buenos Aires, Not set

Akero Clinical Study Site, Broadmeadow, New South Wales

Akero Clinical Study Site, Liverpool, New South Wales

Akero Clinical Study Site, Westmead, New South Wales

Akero Clinical Study Site, Adelaide, South Australia

Akero Clinical Study Site, Caulfield South, Victoria

Akero Clinical Study Site, Epping, Victoria

Akero Clinical Study Site, Frankston, Victoria

Akero Clinical Study Site, Heidelberg, Victoria

Akero Clinical Study Site, Melbourne, Victoria

Akero Clinical Study Site, Murdoch, Western Australia

Akero Clinical Study Site, Nedlands, Western Australia

Akero Clinical Study Site, Perth, Western Australia

Akero Clinical Study Site, Edmonton, Alberta

Akero Clinical Study Site, Hamilton, Ontario

Akero Clinical Study Site, Toronto, Ontario

Akero Clinical Study Site, Vaughan, Ontario

Akero Clinical Study Site, Terrebonne, Quebec

Akero Clinical Study Site, Nice Cedex 3, Alpes-Maritimes

Akero Clinical Study Site, Strasbourg, Bas-Rhin

Akero Clinical Study Site, Limoges Cedex, Haute-Vienne

Akero Clinical Study Site, Clichy, Hauts-de-Seine

Akero Clinical Study Site, Paris, Ile-de-France

Akero Clinical Study Site, Vandœuvre-lès-Nancy, Lorraine

Akero Clinical Study Site, Angers Cedex 9, Maine-et-Loire

Akero Clinical Study Site, Toulouse, Occitanie

Akero Clinical Study Site, Montpellier Cedex 5, Provence Alpes Cote d'Azur

Akero Clinical Study Site, Marseille Cedex 08, Provence-Alpes-Côte d'Azur

Akero Clinical Study Site, Lyon, Rhone-Alpes

Akero Clinical Study Site, Versailles, Yvelines, Île-de-France

Akero Clinical Study Site, Würzburg, Bayern

Akero Clinical Study Site, Frankfurt am Main, Hessen

Akero Clinical Study Site, Mainz, Rheinland-Pfalz

Akero Clinical Study Site, Leipzig, Sachsen

Akero Clinical Study Site, Leipzig, Saxony

Akero Clinical Study Site, Lübeck, Schleswig-Holstein

Akero Clinical Study Site, Berlin, Not set

Akero Clinical Study Site, New Delhi, Delhi

Akero Clinical Study Site, Surat, Gujarat

Akero Clinical Study Site, Vadodara, Gujarat

Akero Clinical Study Site, Thiruvananthapuram, Kerala

Akero Clinical Study Site, Dahegaon, Maharashtra

Akero Clinical Study Site, Nagpur, Maharashtra

Akero Clinical Study Site, Pune, Maharashtra

Akero Clinical Study Site, Jaipur, Rajasthan

Akero Clinical Study Site, Coimbatore, Tamil Nadu

Akero Clinical Study Site, Hyderabad, Telangana

Akero Clinical Study Site, Varanasi, Uttar Pradesh

Akero Clinical Study Site, Kolkata, West Bengal

Akero Clinical Study Site, Petah Tikva, Central District

Akero Clinical Study Site, Ramat Gan, Central District

Akero Clinical Study Site, Haifa, Haifa District

Akero Clinical Study Site, Afula, Northern District

Akero Clinical Study Site, Nahariya, Northern District

Akero Clinical Study Site, Nazareth, Northern District

Akero Clinical Study Site, Jerusalem, Not set

Akero Clinical Study Site, Tel Aviv, Not set

Akero Clinical Study Site, San Giovanni Rotondo, Foggia

Akero Clinical Study Site, Rozzano, Milan

Akero Clinical Study Site, Torino, Turin

Akero Clinical Study Site, Bologna, Not set

Akero Clinical Study Site, Foggia, Not set

Akero Clinical Study Site, Messina, Not set

Akero Clinical Study Site, Milan, Not set

Akero Clinical Study Site, Modena, Not set

Akero Clinical Study Site, Napoli, Not set

Akero Clinical Study Site, Novara, Not set

Akero Clinical Study Site, Daegu, Daegu Gwang'yeogsi [Taegu-Kwangyokshi]

Akero Clinical Study Site, Goyang-Si, Gyeonggi-Do

Akero Clinical Study Site, Incheon, Gyeonggi-do

Akero Clinical Study Site, Seongnam-si, Gyeonggi-Do

Akero Clinical Study Site, Seongnam-si, Gyeonggido [Kyonggi-do]

Akero Clinical Study Site, Daegu, Gyeongsangbugdo [Kyongsangbuk-do]

Akero Clinical Study Site, Seoul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi]

Akero Clinical Study Site, Wrocław, Dolnoslaskie

Akero Clinical Study Site, Krakow, Malopolskie

Akero Clinical Study Site, Warsaw, Mazowieckie

Akero Clinical Study Site, Warszawa, Mazowieckie

Akero Clinical Study Site, Gdańsk, Pomorskie

Akero Clinical Study Site, Gdynia, Pomorskie

Akero Clinical Study Site, Katowice, Slaskie

Akero Clinical Study Site, Poznań, Wielkopolskie

Akero Clinical Study Site, Łódź, Łódzkie

Akero Clinical Study Site, Częstochowa, Śląskie

Akero Clinical Study Site, Manati, Not set

Akero Clinical Study Site, San Juan, Not set

Akero Clinical Study Site, Sabadell, Barcelona

Akero Clinical Study Site, Santander, Cantabria

Akero Clinical Study Site, Majadahonda, Madrid

Akero Clinical Study Site, Valencia, València

Akero Clinical Study Site, Barcelona, Not set

Akero Clinical Study Site, Madrid, Not set

Akero Clinical Study Site, Sevilla, Not set

Akero Clinical Study Site, Olten, Solothurn

Akero Clinical Study Site, Bern, Not set

Akero Clinical Study Site, Sankt Gallen, Not set

Akero Clinical Study Site, Changhua City, Changhua

Akero Clinical Study Site, Taichung City, Taichung

Akero Clinical Study Site, Tainan City, Tainan

Akero Clinical Study Site, Taipei City, Taipei

Akero Clinical Study Site, Kaohsiung, Not set

Akero Clinical Study Site, Tainan, Not set

Akero Clinical Study Site, Taoyuan, Not set

Akero Clinical Study Site, Yenimahalle, Ankara

Akero Clinical Study Site, Bornova, Izmir

Akero Clinical Study Site, Bursa, Not set

Akero Clinical Study Site, Rize, Not set

Akero Clinical Study Site, Birmingham, England

Akero Clinical Study Site, Cambridge, England

Akero Clinical Study Site, Liverpool, England

Akero Clinical Study Site, London, England

Akero Clinical Study Site, Newcastle-upon-Tyne, England

Conditions: NASH With Fibrosis, MASH With Fibrosis

Learn More ›

APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML

NCT06634394

Recruiting

A multi-center, open-label, dose-finding study of five dose levels of APVO436 in combination with venetoclax and azacitidine (ven/aza) in adult patients with newly diagnosed, CD123+ AML.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/09/2025

Locations: Colorado Blood Cancer Institute, Denver, Colorado +6 locations

Conditions: Acute Myeloid Leukemia (AML)

Learn More ›